This site is intended for healthcare professionals outside the US


Print |

Tumor control for patients with advanced neuroendocrine tumors (NET) of the midgut or unknown primary tumor location1:

  • The recommended dose of Sandostatin® LAR® is 30 mg administered every 4 weeks
  • Treatment with Sandostatin® LAR® for tumor control should be continued in the absence of tumor progression

Symptom control for patients with symptoms associated with functional gastroenteropancreatic NET:

For patients not currently receiving s.c. Sandostatin® Injection1

  • It is recommended to start treatment with the administration of 20 mg Sandostatin® LAR® at 4-week intervals

For patients currently receiving s.c. Sandostatin® Injection1

  • It is recommended that patients should continue at the previously effective dosage of s.c. Sandostatin® Injection for 2 weeks after the first injection of Sandostatin® LAR®
Patients who achieve good symptom control with 20 mg of Sandostatin® LAR® after 3 months may have their dose lowered to 10 mg.1 For patients in whom symptoms are only partially controlled after 3 months of treatment, the dose may be increased to 30 mg of Sandostatin® LAR® every 4 weeks.1
Guidelines* recommend 30 mg of Sandostatin® LAR® for tumor control.2
*ENETS Consensus Guidelines recommend Sandostatin® LAR® 30 mg for antiproliferative purposes.2

1. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2018. 2. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176.